{"id":"boostrix-tm","safety":{"commonSideEffects":[{"rate":"40-75","effect":"Injection site pain, redness, or swelling"},{"rate":"30-40","effect":"Headache"},{"rate":"20-30","effect":"Fatigue"},{"rate":"20-30","effect":"Myalgia (muscle pain)"},{"rate":"5-15","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Boostrix contains inactivated toxoids of diphtheria and tetanus, along with acellular pertussis antigens, which trigger adaptive immune responses. Upon vaccination, the immune system generates specific antibodies and cellular immunity against these three bacterial pathogens, providing protection against infection and disease. The vaccine is administered as a booster dose to maintain or restore immunity in adolescents and adults.","oneSentence":"Boostrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:45.936Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Booster vaccination against diphtheria, tetanus, and pertussis in adolescents (10 years and older) and adults"},{"name":"Pertussis protection in pregnant women (to provide passive immunity to infants)"}]},"trialDetails":[{"nctId":"NCT03942406","phase":"PHASE2","title":"Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults","status":"COMPLETED","sponsor":"ILiAD Biotechnologies","startDate":"2019-06-15","conditions":"Pertussis, Whooping Cough","enrollment":300},{"nctId":"NCT01094171","phase":"PHASE4","title":"Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-03","conditions":"Poliomyelitis","enrollment":400},{"nctId":"NCT00808444","phase":"PHASE3","title":"Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-01-05","conditions":"Infections, Streptococcal","enrollment":466},{"nctId":"NCT01362322","phase":"PHASE4","title":"Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-01","conditions":"Diphtheria, Tetanus, Acellular Pertussis","enrollment":671},{"nctId":"NCT00369824","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-26","conditions":"Infections, Papillomavirus","enrollment":1330},{"nctId":"NCT00426361","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-13","conditions":"Infections, Papillomavirus","enrollment":751},{"nctId":"NCT00871000","phase":"PHASE3","title":"Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04-01","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":303},{"nctId":"NCT00610168","phase":"PHASE4","title":"Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01-01","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":82},{"nctId":"NCT00376779","phase":"PHASE2","title":"Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":450},{"nctId":"NCT00879827","phase":"PHASE3","title":"Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-09","conditions":"Diphtheria, Poliomyelitis, Hepatitis B","enrollment":60},{"nctId":"NCT00258154","phase":"PHASE3","title":"V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-02","conditions":"Rotavirus Disease","enrollment":403}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["dTpa vaccine"],"phase":"marketed","status":"active","brandName":"Boostrix TM","genericName":"Boostrix TM","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Boostrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens. Used for Booster vaccination against diphtheria, tetanus, and pertussis in adolescents (10 years and older) and adults, Pertussis protection in pregnant women (to provide passive immunity to infants).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}